Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, ...

The instances of ARIA were primarily seen in participants treated with AL002. “We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer’s disease and remain ...

Mizuho says Alector’s (ALEC) top-line Phase 2 results for AL002 in Alzheimer’s disease “were non-equivocal, with negative signals on all primary or secondary endpoints.” The outcome comes ...

The instances of ARIA were primarily seen in participants treated with AL002. “We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer’s disease and ...